These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11340368)

  • 41. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.
    Venneri A; Shanks MF; Staff RT; Pestell SJ; Forbes KE; Gemmell HG; Murray AD
    Neuroreport; 2002 Jan; 13(1):83-7. PubMed ID: 11924899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rivastigmine in vascular dementia.
    Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
    Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.
    Grace J; Daniel S; Stevens T; Shankar KK; Walker Z; Byrne EJ; Butler S; Wilkinson D; Woolford J; Waite J; McKeith IG
    Int Psychogeriatr; 2001 Jun; 13(2):199-205. PubMed ID: 11495394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rivastigmine in outpatient services: experience of 114 neurologists in Austria.
    Schmidt R; Lechner A; Petrovic K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):81-5. PubMed ID: 11890189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
    Selai CE; Trimble MR; Rossor MN; Harvey RJ
    BMJ; 1999 Sep; 319(7210):641-2. PubMed ID: 10523095
    [No Abstract]   [Full Text] [Related]  

  • 46. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
    Moerkens RM; Dhondt AD
    Ned Tijdschr Geneeskd; 2003 Apr; 147(14):679; author reply 679. PubMed ID: 12712654
    [No Abstract]   [Full Text] [Related]  

  • 48. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
    Mol JA
    Ned Tijdschr Geneeskd; 2003 Apr; 147(14):679; author reply 679. PubMed ID: 12712655
    [No Abstract]   [Full Text] [Related]  

  • 49. Surprising discovery with Alzheimer's medication.
    Thacker PD
    Drug Discov Today; 2003 May; 8(9):379-80. PubMed ID: 12706648
    [No Abstract]   [Full Text] [Related]  

  • 50. No additional benefit of HRT on response to rivastigmine in menopausal women with AD.
    Rigaud AS; André G; Vellas B; Touchon J; Pere JJ;
    Neurology; 2003 Jan; 60(1):148-9. PubMed ID: 12525745
    [No Abstract]   [Full Text] [Related]  

  • 51. Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points.
    Storosum JG; van Zwieten-Boot BJ; Elferink AJ
    BMJ; 1999 Sep; 319(7210):642. PubMed ID: 10523096
    [No Abstract]   [Full Text] [Related]  

  • 52. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
    Scheepmaker AJ; Horstink MW; Hoefnagels WH; Strijks FE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(1):32-5. PubMed ID: 12564296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
    Enz A; Boddeke H; Gray J; Spiegel R
    Ann N Y Acad Sci; 1991; 640():272-5. PubMed ID: 1776750
    [No Abstract]   [Full Text] [Related]  

  • 54. New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
    J Clin Psychiatry; 2000 Apr; 61(4):307-15. PubMed ID: 10830158
    [No Abstract]   [Full Text] [Related]  

  • 55. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
    Farlow M; Anand R; Messina J; Hartman R; Veach J
    Eur Neurol; 2000; 44(4):236-41. PubMed ID: 11096224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rivastigmine in the treatment of alcohol-induced persisting dementia.
    Gibson RC; Barnaby L
    West Indian Med J; 2003 Mar; 52(1):59-61. PubMed ID: 12806761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study].
    Cruz Jentoft AJ; Hernández B
    Neurologia; 2014; 29(1):1-10. PubMed ID: 23582372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease?
    Cantisani TA; Celani MG; Righetti E
    Neuroepidemiology; 2004; 23(4):209-10. PubMed ID: 15272224
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.